Drug Trial Radar · NCT04712643
A Study of TACE Combined With Atezolizumab Plus Bevacizumab or TACE Alone in Patients With Untreated Heaptocellular Carcionma
Last checked: Nov 20, 2026Latest source record: Oct 26, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
342
Actual
Start
Mar 12, 2021
Primary completion
Feb 1, 2029
Study completion Feb 1, 2029
Sponsor
- Lead sponsor
- Hoffmann-La RocheRoche (Genentech) (RHHBY)
- Sponsor type
- Industry
- First posted
- Jan 15, 2021
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study will evaluate the efficacy and safety of atezolizumab plus bevacizumab combined with on-demand TACE compared to on-demand TACE alone in participants with hepatocellular carcinoma who are at high risk of poorer outcome following TACE treatment.
Conditions
- Hepatocellular Carcinoma
Interventions
AtezolizumabDrug
Atezolizumab will be administered by IV infusion at a fixed dose of 1200 mg on Day 1 of each 21-day cycle until participant experience loss of clinical benefit as evaluated by the investigator or unacceptable toxicity or withdrawal of informed consent.
BecavizumabDrug
Bevacizumab will be administered by IV infusion at a fixed dose of 15 mg/kg on Day 1 of each 21-day Cycle.
Transarterial chemoembolization (TACE)Device
TACE will be performed by clinical demand.
Primary outcomes
What the sponsor says the trial is designed to measure.
- TACE Progression-Free Survival (TACE PFS) as Determined by InvestigatorTime frame: Randomization to untreatable progression or TACE failure/refractoriness or death (up to approximately 46 months)
- Overall Survival (OS)Time frame: Randomization to death from any cause (up to approximately 94 months)
Locations
40 sites in 2 countries. Site status is shown where the registry gives one.
Anhui Provincial Hospital
Anhui, China
Peking University First Hospital
Beijing, China
Peking University People's Hospital
Beijing, China
Beijing You An Hospital
Beijing, China
Beijing Tsinghua Changgung Hospital
Beijing, China
Hunan Cancer Hospital
Changsha, China
West China Hospital, Sichuan University
Chengdu, China
The First Affiliated Hospital, Chongqing Medical University
Chongqing, China
Southwest Hospital , Third Military Medical University
Chongqing, China
The 900th Hospital of PLA joint service support force
Fuzhou, China
The First Affiliated Hospital Of Fujian Medical University
Fuzhou, China
Fujian Cancer Hospital
Fuzhou, China
Mengchao Hepatobiliary Hospital Of Fujian Medical University
Fuzhou, China
Sun Yet-sen University Cancer Center
Guangzhou, China
Nanfang Hospital, Southern Medical University
Guangzhou, China
Zhejiang Cancer Hospital
Hangzhou, China
Harbin Medical University Cancer Hospital
Harbin, China
Jiangsu Cancer Hospital
Nanjing, China
Jiangsu Province Hospital (the First Affiliated Hospital With Nanjing Medical University)
Nanjing, China
Guangxi Cancer Hospital of Guangxi Medical University
Nanning, China
The First Affiliate Hospital of Guangxi Medical University
Nanning, China
Fudan University Shanghai Cancer Center
Shanghai, China
Renji Hospital Shanghai Jiaotong University School of Medicine
Shanghai, China
Zhongshan Hospital Fudan Unvierstiy
Shanghai, China
Shengjing Hospital of China Medical University
Shenyang, China
Tianjin Cancer Hospital
Tianjin, China
The First Affiliated Hospital of Xi'an Jiaotong University
Xi'an, China
Xi'an Inernational Medical Center Hospital
Xi'an, China
Henan Cancer Hospital
Zhengzhou, China
Zhuhai People's Hospital
Zhuhai, China
Aichi Cancer Center
Aichi, Japan
Chiba University Hospital
Chiba, Japan
Kurume University Hospital
Fukuoka, Japan
Hiroshima University Hospital
Hiroshima, Japan
Yokohama City University Medical Center
Kanagawa, Japan
Kanagawa Cancer Center
Kanagawa, Japan
Kitasato University Hospital
Kanagawa, Japan
The University of Osaka Hospital
Osaka, Japan
Kindai University Hospital
Osaka, Japan
Toranomon Hospital
Tokyo, Japan
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.